Opko Health has entered a definitive agreement to acquire Prost-Data, which does business as OURLab, a Nashville, Tenn.-based CLIA laboratory.
The acquisition will provide Opko with a platform to support the US commercial launch of its 4Kscore protein biomarker prostate cancer test, the company said. Opko is planning a "near-term" US launch of the test as a laboratory-developed test.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
